Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension

Journal of Human Hypertension

Volumn 30, Issue 7, 2016, Pages 424-429

  Yavuzer, H ^a   Cengiz, M ^a   Yavuzer, S ^a   Riza Altiparmak, M ^a   Korkmazer, B ^a   Balci, H ^a   Yaldiran, A L ^a   Uzun, H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 33; PENTRAXIN 3; PROCALCITONIN; AUTACOID; BIOLOGICAL MARKER; CALCITONIN; IL33 PROTEIN, HUMAN; SERUM AMYLOID P;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; WHITE COAT HYPERTENSION; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; PATHOPHYSIOLOGY; UPREGULATION;

ADULT; BIOMARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCITONIN; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-33; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; UP-REGULATION; WHITE COAT HYPERTENSION;

EID: 84930368482     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.59     Document Type: Article

References (35)

1. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 152-158
2. Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care 2008; 31: S185-S189
3. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259: 225-228
4. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733
6. Yasunaga T, Ikeda S, Koga S, Nakata T, Yoshida T, Masuda N, et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J 2014; 55: 160-164
7. Bottazzi B, Bastone A, Doni A, Garlanda C, Valentino S, Deban L, et al. The long pentraxin PTX3 as a link among innate immunity, inflamation and female fertility. J Leukoc Biol 2006; 79: 909-912
8. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-1608
9. Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS, et al. AtheroGene Study Investigators. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 2011; 75: 1184-1191
10. Mallamaci F, Leonardis D, Pizzini P, Cutrupi S, Tripepi G, Zoccali C. Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. J Hypertens 2013; 31: 1424-1430
11. Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080-2089
12. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22
13. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322: 531-536
14. O'Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, et al. Use and interpretation of Ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128-1134
15. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406
16. Pauletto P, Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 2006; 21: 850-853
17. Lu HH, Guo ZR, Hu XS, Wu M, Zhou MH, Zhou ZY. The prospective study of association between C-reactive protein and hypertension in community population. Zhonghua Yu Fang Yi Xue Za Zhi 2013; 47: 1026-1030
18. Zhang M, Wang G, Wang A, Tong W, Zhang Y. Association of hypertension with coexistence of abnormal metabolism and inflammation and endothelial dysfunction. Blood Press 2013; 22: 151-157
19. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49-57
20. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433
21. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861
22. Ozdogan M, Bozcuk H, Coban E. Low-grade inflammation in white-coat hypertension. Med Sci Monit 2007; 13: CR570-CR573
23. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951
24. Niskanen L, Laaksonen DE, Nyyssönen K, Punnonen K, Valkonen VP, Fuentes R, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859-865
25. Peer M, Boaz M, Zipora M, Shargorodsky M. Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors. Int J Angiol 2013; 22: 223-228
26. Turak O, Özcan F, Canpolat U, Isleyen A, Cebeci M, Öksüz F, et al. Increased echocardiographic epicardial fat thickness and high-sensitivity CRP level indicate diastolic dysfunction in patients with newly diagnosed essential hypertension. Blood Press Monit 2013; 18: 259-264
27. Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens 2011; 5: 395-400
28. Gupta V, Sachdeva S, Khan AS, Haque SF. Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi J Kidney Dis Transpl 2011; 22: 97-103
29. Parlak A, Aydogan U, Iyisoy A, Dikililer MA, Kut A, Cakir E, et al. Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg 2012; 12: 298-304
30. Büyükkaya E, Karakas MF, Kurt M, Motor S, Akçay AB, Büyükkaya S, et al. The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Turk Kardiyol Dern Ars 2013; 41: 290-295
31. Yano Y, Matsuda S, Hatakeyama K, Sato Y, Imamura T, Shimada K, et al. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010; 65: 547-552
32. Ataoglu HE, Yilmaz F, Uzunhasan I, Cetin F, Temiz L, Döventas YE, et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res 2010; 38: 52-61
33. Schiopu A, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med 2012; 272: 484-491
34. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339-346
35. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117-3126